About Event

Welcome to the 6th RNAi-Based Therapeutics Summit

As RNAi excitement continues to grow, join your peers for 3 jam-packed days dedicated to advancing your RNAi candidates into clinically relevant therapies. Curated with insight from Benitec Biopharma, Switch Therapeutics, Novartis, and Sirnaomics, this RNAi-focused agenda will cover all things RNAi, from maximizing bioavailability with oligonucleotide conjugates, streamlining translation, overcoming off-target effects and maintaining purity during scale-up and manufacturing.

25+ Expert Speakers will be sharing data and empowering you to:

Seize the value of novel delivery systems to maximize bioavailability and precision targeting to a wider range of tissues with insights from SanegeneBio, Avidity Biosciences and Sapreme Technologies

Unlock the full potential of RNAi therapy by reaching previously undruggable extra-hepatic targets including the CNS, placenta, muscle and kidney, with data from Comanche Biopharma, Novo Nordisk and Switch Therapeutics

Revolutionize RNAi design and delivery by employing cutting edge generative AI and deep-learning based platforms to advance stable, precise extra-hepatic targeting, with expertise from Nosis Bio, Tallas Biotech and ProteinQure

Enhance the stability, efficacy and tolerability of RNAi payloads through clever chemical modifications which suppress off-target activity and improve durability, with research from Alnylam, Novartis, and Stony Brook University 

Maximize the success of early-stage RNAi platforms and assets and attract investment and meaningful partnerships, with insight from Sunrise Bioventures and Broadview Ventures

New & Noteworthy Sessions

Chad Miller, Nosis Bio

"Deep Learning-based Design of Cell-targeting Ligands Enables Cell-specific, Functional siRNA Delivery in Multiple Extra-hepatic Tissues"


Chad Miller, Head of Research, Nosis Bio

Yuanyuan Jin, Bound Therapeutics

“Targeted Extra-Hepatic Delivery of Custom Oligonucleotide-Peptide Conjugates for Enhanced Tumor Bioavailability, Efficacy, & Safety in a Breast Cancer Model


Yuanyuan Jin, Co-founder & Chief Operating Officer, Bound Therapeutics

Vignesh Narayan Hariharan, Director of Biology, Comanche Biopharma & Instructor, UMass Chan Medical School

“Delivery of siRNA to the Placenta for the Treatment of Preeclampsia”


Vignesh Narayan Hariharan, Director of Biology, Comanche Biopharma & Instructor, UMass Chan Medical School

David Sharp, MicroCures

Novel siRNA Platform for Cellular-Driven Tissue Repair & Regeneration”


David Sharp, Chief Executive Officer, MicroCures

Mohammad Shadid, Korro Bio
Hanhua Huang, Avidity Biosciences

Workshop B: “Streamlining Translation & De-risking RNAi Therapeutic Development with Optimal Selection of Preclinical Models & Appropriate Assays to Ensure Tolerable, Potent Therapies”


Mohammad Shadid, Vice President, Preclinical Development, Korro Bio

Hanhua Huang, Vice President, Biology, Avidity Biosciences